26.9 C
Vientiane
Thursday, July 17, 2025
spot_img
Home Blog Page 551

MaintainX Recognized with Frost & Sullivan’s 2025 North American Technology Innovation Leadership Award for Pioneering AI-Powered Maintenance and Asset Optimization in North America

MaintainX empowers frontline teams with innovative AI-powered maintenance tools, real-time asset insights, and seamless integrations that enhance operational efficiency

SAN ANTONIO, April 9, 2025 /PRNewswire/ — Frost & Sullivan recently researched the artificial intelligence (AI)powered asset maintenance and frontline execution platforms market and, based on its findings, recognizes MaintainX with the 2025 North American Technology Innovation Leadership Award. MaintainX is a forward-thinking provider of AI-driven maintenance and operations management solutions that strengthen frontline teams with real-time asset insights, reliable predictive maintenance, and streamlined workflow automation.

MaintainX’s AI-powered platform transforms organizations’ maintenance and asset operations by integrating highly intelligent automation, real-time analytics, and a mobile-first experience. The company’s solution is designed to reduce unplanned downtime, optimize asset utilization, and boost workforce productivity across industries such as manufacturing, facilities, distribution centers and other physical asset driven industries. One of the standout aspects of MaintainX is its superior ability to provide real-time asset availability and parts usage data, allowing frontline professionals to avoid costly stockouts and maintenance delays. Additionally, the platform’s advanced reporting and predictive analytics equip organizations with actionable insights, helping them anticipate equipment failures, optimize inventory management, and drive cost savings.

Another key differentiator is the MaintainX CoPilot, which redefines how organizations access and utilize institutional knowledge. The tool enables technicians and managers to quickly retrieve critical information, standardize procedures, and accelerate operational decision-making. These qualities make MaintainX CoPilot a vital solution for preserving knowledge and ensuring long-term maintenance efficiency and business continuity.

“MaintainX CoPilot is an AI-powered maintenance assistant transforming how teams access and utilize institutional knowledge. By analyzing original equipment manufacturer manuals and work order history, the assistant can help technicians and managers quickly find critical information, create standardized procedures, and get real-time answers to maintenance questions. This purpose-built AI tool goes beyond generic chatbots, making complex technical documentation more accessible and actionable for maintenance teams while helping preserve valuable institutional knowledge as experienced workers transition,” said Sankara Narayanan, industry director at Frost & Sullivan.

The company leverages cutting-edge AI and machine learning (ML) technologies to revolutionize maintenance processes. Its predictive maintenance capabilities allow organizations to detect failures before they occur, drastically reducing downtime and maintenance costs. MaintainX also integrates with IoT sensors and SCADA systems, enabling real-time data collection that significantly enhances asset health and performance visibility.

Moreover, MaintainX simplifies complex maintenance tasks and facilitates digital transformation by harnessing AI-driven automation. Its original AI workflows allow organizations to automate maintenance planning, optimize resource allocation, and standardize best practices across multiple facilities. These intelligent features maximize productivity and ensure that maintenance teams can make data-driven decisions with outstanding speed and accuracy.

“Outside of using data to give customers more visibility about what is happening on their facility floor, MaintainX incorporates AI and ML technologies in its solution to enable customers to simplify and accelerate maintenance. Its Applied AI workflows and predictive maintenance unearth several compelling use cases,” noted Sankara Narayanan.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

“At MaintainX, we’re committed to transforming how organizations approach maintenance and operations through continual innovation. Our platform isn’t just about fixing equipment, it’s about empowering frontline teams with real-time insights and predictive capabilities that drive productivity and extend asset lifecycles. The MaintainX CoPilot represents our vision for the future of maintenance: preserving institutional knowledge, standardizing best practices, and making technical expertise accessible to everyone. We’re honored to receive this recognition from Frost & Sullivan, which validates our approach to solving critical challenges for maintenance teams across industries,” said Hugo Dozois-Caouette, MaintainX CTO and Co-Founder.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Ashley Shreve
Marketing Coordinator – Best Practices Recognition
Ashley.Weinkauf@frost.com
Phone: +1.210.844.2505

About MaintainX
Headquartered in San Francisco, MaintainX is a technology company pioneering a mobile-first approach to intelligent, software-defined maintenance and operations management. It empowers frontline teams to manage work orders, assets, parts inventory, and purchase orders more efficiently, reducing unexpected downtime and boosting production capacity. MaintainX leverages AI and IIoT to connect asset and work data, providing real-time insights that drive proactive maintenance and operational excellence for 10K+ customers across physical asset-driven industries. MaintainX operates in North America with additional support worldwide. MaintainX is reimagining how maintenance and operations can be designed and managed to address the realities of today and the future ahead. For more information, visit www.maintainx.com.

MaintainX® is a registered trademark of MaintainX Inc.

Contacts
For media inquiries: press@getmaintainx.com

Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

  • Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals
  • Abstract honored with prestigious “Abstracts of Distinction” award by AAN Science Committee, recognizing top quality and interest
  • Phase I clinical trial for RAG-17 advancing as planned with dosing successfully completed for the first two cohorts

NANTONG, China and SAN DIEGO, April 9, 2025 /PRNewswire/ — Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing pioneering RNA-based medicines, today announced that the final, positive results from the Investigator-Initiated Trial (IIT) of RAG-17, a novel siRNA therapy targeting SOD1 for Amyotrophic Lateral Sclerosis (ALS), were presented for the first time during an oral presentation at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego, CA.

The presentation, titled “RAG-17 a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial,” was delivered on April 7th by Dr. Weiqi Chen of Beijing Tiantan Hospital, Capital Medical University, on behalf of the team led by the study’s Principal Investigator, Dr. Yilong Wang.

Highlighting the significance and quality of the research, the abstract was selected by the AAN Science Committee for the prestigious “Abstracts of Distinction” award. This honor is awarded to abstracts deemed to be the top in their topic category based on the quality of the study and interest to the neurologic community. This follows Ractigen’s previous announcement in September 2024 regarding the positive initial clinical data obtained from this IIT study.

Key Findings from the RAG-17 IIT Study Presented at AAN 2025:
The final data from the IIT (NCT05903690), a first-in-human, open-label, dose-escalation study involving six SOD1-ALS patients over 240 days, demonstrated:

  • Favorable safety and tolerability: RAG-17 was generally well-tolerated with intrathecal administration. No dose-limiting toxicities (DLTs) or serious adverse events (SAEs) were reported. Most adverse events were mild and transient.
  • Significant target engagement: Treatment with RAG-17 led to a substantial reduction of SOD1 protein levels in the cerebrospinal fluid (CSF), exceeding 50% in five out of six subjects, confirming potent target engagement in the central nervous system.
  • Substantial reduction in key biomarker: Significant reductions in plasma neurofilament light chain (NfL) levels, a key biomarker of neuroaxonal damage, were observed, suggesting a potential impact on neurodegeneration.
  • Encouraging clinical efficacy signals: Patients treated with RAG-17 showed encouraging trends in clinical outcome measures. The average decrease in the ALS Functional Rating Scale-Revised (ALSFRS-R) score was 2.17 points over the study period (equivalent to a 0.29-point decline per month), suggesting potential slowing of functional decline. Forced Vital Capacity (FVC) remained stable in most patients, with two showing a significant increase from baseline.

Phase I Trial Update
Ractigen Therapeutics also reports that a Phase I clinical trial for RAG-17 is progressing smoothly. This randomized, double-blind, placebo-controlled dose escalation study is designed to further evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in SOD1-ALS patients. Following the first patient dosing announced in December 2024, two cohorts have now successfully completed. The trial is being conducted across multiple sites, led by investigators including Dr. Yilong Wang at Beijing Tiantan Hospital, Dr. Zhiying Wu at the Second Affiliated Hospital of Zhejiang University School of Medicine, and Dr. Huifang Shang at West China Hospital, Sichuan University.

“We are thrilled that our RAG-17 program has been honored with an Abstract of Distinction at the AAN 2025 meeting. This recognition highlights the significance of our work in addressing the unmet needs of SOD1-ALS patients,” said Dr. Long-Cheng Li, President and CEO of Ractigen Therapeutics. “The positive final data from our IIT, demonstrating favorable safety, robust target knockdown, and encouraging biomarker and clinical signals, combined with the ongoing progress in our Phase I trial, reinforce our commitment to bringing this innovative therapy to those who need it most.”

Dr. Yilong Wang, Principal Investigator of the RAG-17 IIT study and Vice President of Beijing Tiantan Hospital, Capital Medical University, commented, “The results presented at AAN 2025 demonstrate the potential of RAG-17 to significantly impact the lives of patients with SOD1-ALS. The safety profile and early efficacy signals, particularly the significant reduction in CSF SOD1 and plasma NfL levels alongside stable functional measures, are encouraging. We look forward to continuing our work in the Phase I study to further validate these findings and bring this therapy closer to clinical application.”

About RAG-17
RAG-17 is an investigational siRNA therapeutic candidate designed using Ractigen’s proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial Amyotrophic Lateral Sclerosis (ALS). By reducing the production of the toxic mutant SOD1 protein, RAG-17 aims to slow or halt the progression of SOD1-ALS.

About ALS
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death, typically within three to five years of diagnosis. SOD1 gene mutations account for approximately 10-20% of familial ALS cases and about 1-2% of sporadic ALS cases. There remains a critical unmet medical need for effective treatments that can slow or stop disease progression.

About Ractigen Therapeutics 
Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.

 

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

SEOUL, South Korea, April 9, 2025 /PRNewswire/ — Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market.

Activin/BMP7 Chimera Protein Technology Registered in China

Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in South Korea in November last year, this marks the company’s first successful international patent registration as part of its efforts to secure global intellectual property rights through the PCT (Patent Cooperation Treaty) route in key regions such as the EU, the United States, and China.

The technology basis is an AI-enhanced innovative protein structure generator designed to provide therapeutics that overcome the current limitations of standard of care treatment in osteoarthritis—a condition for which only symptom management options currently exist. This technology represents a wholly new approach to protein design and is expected to address the underlying causes of disease. This treatment approach may significantly improve treatment outcomes not only for osteoarthritis but also for a wide range of other musculoskeletal disorders.

In particular, the DRT-101 chimeric protein, which recombines the natural BMP7 and Activin proteins into a wholly novel structure, has already been shown to enhance both therapeutic efficacy and safety in vivo, in studies conducted between 2020 and 2024 at the University of California, San Diego, School of Medicine.

Senyon Choe, Darnatein Chief Executive Officer, stated, “The protein design technology now also patented in China has been developed over years from a core platform strategy to the current technology with the potential to revolutionize the global OA treatment market. Securing intellectual property rights in China, one of the largest markets in the world, is a crucial stepping-stone for our global expansion.”

Constance Höfer, Chief Scientific Officer of OSR Holdings, stated, “Darnatein’s groundbreaking technology represents a wholly new, AI-enhanced approach to therapeutic protein design. The successful patent registration in China underscores the novelty and relevance of this technology to the development of better treatment options for OA patients worldwide.”

Global Technological Competitiveness and Licensing Potential

The osteoarthritis treatment market continues to grow, due to globally aging populations. In 2023, the market size reached approximately USD 8.9 billion and is projected to grow at an average annual rate of about 7%, reaching approximately USD 16.1 billion by 2032. China is experiencing rapid population aging and a surge in osteoarthritis cases, making it a highly promising market.

Industry experts have remarked, “Darnatein’s Activin/BMP7 chimera technology offers a superior profile to be developed into a potential DMOAD, or disease-modifying OA drug, compared to existing standard of care for osteoarthritis treatments,” adding, “Big Pharma is looking for novel treatments that can slow, stop, or even reverse the cartilage degeneration and joint damage that occurs with OA. On this backdrop, Darnatein’s chimeric protein approach represents a paradigm shift away from only symptom relief (e.g. painkillers and anti-inflammatories) to treatment options targeting the underlying pathobiology of OA”

Darnatein is currently completing preclinical studies with DRT-101, its degenerative OA treatment candidate, with the goal to initiate Phase 1 clinical trials later this year.

About Darnatein

Founded in 2012, Darnatein is a biotherapeutics company based in South Korea developing a pipeline of innovative treatments for osteoarthritis and bone fusion, including DRT-101 as a ground breaking disease-modifying OA drug (DMOAD) candidate. Darnatein was established by Dr. Senyon Choe, one of the co-founders of the structural protein laboratory of the prestigious Salk Institute for Biological Studies in La Jolla, CA, and a faculty member of UC San Diego since 1993. Darnatein operates as a wholly owned subsidiary of OSR Holdings, Inc. following its acquisition in 2023. 

About OSR Holdings, Inc.

OSR Holdings, Inc. is a global healthcare company dedicated to advancing biomedical innovation. Through its subsidiaries, OSR is engaged in oncology immunotherapies, degenerative disease biologics, and medical device distribution. OSR’s vision is to acquire and operate a portfolio of innovative healthcare companies, improving patient care through cutting-edge research and development. For more information, visit www.OSR-Holdings.com.

Contact

ir@osr-holdings.com

 

Asia Health & Medlab Asia Rebrands to WHX and WHX Labs in Kuala Lumpur and Bangkok

KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ — The global event organisation leader Informa Markets revealed a major rebranding of its healthcare exhibitions portfolio which resulted in the formation of WHX (World Health Expo). WHX rebrands its healthcare events across Southeast Asia to WHX Kuala Lumpur, WHX Labs Kuala Lumpur, WHX Bangkok and WHX Labs Bangkok. Through this strategic shift WHX becomes a worldwide platform that drives innovation and collaboration and advances progress in healthcare and medical laboratory sectors.

WHX Kuala Lumpur and WHX Labs Kuala Lumpur will take place from July 16 through 18, 2025, at The Malaysia International Trade and Exhibition Centre (MITEC) in Kuala Lumpur has established a new standard for industry engagement. Through strategic partnerships with Malaysia External Trade Development Corporation (MATRADE) and Association of Malaysian Medical Industries (AMMI) alongside other prominent healthcare and laboratory associations this event has solidified its position as a key event in Southeast Asia’s healthcare field.

The WHX rebrand signifies Informa Markets’ new direction in healthcare events worldwide and for Southeast Asia while demonstrating a progressive strategy to strengthen industry connections and promote knowledge sharing and innovative medical device and laboratory technology showcase.

After successfully serving Southeast Asia for 11 years, the transformation of Asia Health & Medlab Asia into WHX and WHX Labs in both Kuala Lumpur and Bangkok represents an exciting new beginning.” said Ms. Rungphech (Rose) Chitanuwat, Regional Portfolio Director, ASEAN at Informa Markets. “This transformation demonstrates our dedication to progressing the healthcare and medical device sectors along with medical laboratories throughout Southeast Asia and the broader Asian region. Through the powerful foundation established by Asia Health & Medlab Asia this fresh identity strengthens our promise to develop Southeast Asia’s leading platform where healthcare experts join industry stakeholders, industry leaders and healthcare professionals to connect and innovate the region’s future healthcare landscape.”

Informa Markets has developed a single comprehensive event through WHX Kuala Lumpur and WHX Labs Kuala Lumpur to unite healthcare professionals with industry leaders and stakeholders who advance technology and discussions in healthcare and medical device sectors. Through this integrated platform attendees will experience direct access to new developments in medical equipment, diagnostics, digital health solutions and medical laboratory science which enables them to explore leading-edge innovations that transform healthcare delivery.

Nicha Chamchumrus, Senior Event Manager of WHX Kuala Lumpur and WHX Lab Kuala Lumpur, added: “WHX Kuala Lumpur and WHX Lab Kuala Lumpur will display world-class medical devices and medical laboratory technologies alongside creating essential partnerships that will propel healthcare innovations throughout Southeast Asia. Our conference program is undergoing extensive improvements to establish a strong platform for analyzing key industry challenges and opportunities. The conference will offer attendees in-depth explorations of essential subjects while featuring extensive interactive sessions and a diverse array of expert speakers to encourage meaningful discussions and develop practical solutions for Southeast Asia’s healthcare future.

WHX Kuala Lumpur alongside WHX Labs Kuala Lumpur will establish a vital platform to create partnerships and tackle industry challenges while facilitating important discussions about healthcare delivery for Southeast Asia’s swiftly changing healthcare sector.

Asia Health & Medlab Asia are now WHX Kuala Lumpur and WHX Labs Kuala Lumpur, taking place on 16–18 July 2025 at MITEC, Kuala Lumpur, Malaysia.
Asia Health & Medlab Asia are now WHX Kuala Lumpur and WHX Labs Kuala Lumpur, taking place on 16–18 July 2025 at MITEC, Kuala Lumpur, Malaysia.

 

XCMG Showcases Green Innovation and Intelligent Solutions at bauma 2025, Reinforcing Global Leadership

XCMG Accelerates European Growth with Localized Services, Green Tech, and Strategic Partnerships

MUNICH, April 9, 2025 /PRNewswire/ — At bauma 2025, the world’s premier trade fair for construction machinery, XCMG Machinery (“XCMG”, SHE: 000425) unveiled its latest breakthroughs in intelligent, low-carbon technologies. With over 60 cutting-edge products across seven categories and integrated scenario-driven solutions, XCMG is leading the charge toward a sustainable future under the theme Solid Innovation for Green Tomorrow.

XCMG showcases green, smart tech at bauma 2025, expanding Europe with localized solutions
XCMG showcases green, smart tech at bauma 2025, expanding Europe with localized solutions

Intelligent + Low-Carbon: Pioneering New Energy Solutions

Over 40% of XCMG’s showcased products feature new energy technologies, aligning with the expo’s green vision. Highlights include:

  • The XCA60_EV, the world’s first hybrid all-terrain crane developed for Europe, enabling fully zero-emission operations.
  • A suite of smart, full-scenario solutions for road construction, including electric pavers, milling machines, and compact rollers.
  • The XZ450E-R horizontal directional drill, which boosts steering speed by 200% while reducing slurry consumption by 60%.

“XCMG remains committed to advancing engineering technology to empower a sustainable future. Our mission is to deliver efficient, intelligent, and eco-friendly lifecycle solutions for global clients,” said Mr. Yang Dongsheng, Chairman of XCMG Group and XCMG Machinery. “Today, 19% of our product portfolio comprises green innovations under our ‘Green Mountain’ new energy line, with full electrification across all series underway.”

XCMG launched its next-gen Xrea Global Telematics Platform, integrating IoT, big data, cloud computing, and AI to enable seamless cross-border fleet management. Supporting 10+ languages via PC and mobile interfaces, the platform offers real-time diagnostics, predictive maintenance, and data-driven optimization—empowering clients to manage equipment anytime, anywhere.

In partnership with Germany’s Schwing GmbH, XCMG debuted the Ultra Eco, a pure electric concrete mixer, and Schwing’s first all-electric pump truck. These innovations mark a leap forward in zero-emission, high-efficiency machinery for global markets.

“By combining Schwing’s expertise with XCMG’s innovation, we aim to refine our offerings for Europe’s specialized markets. Our localized strategy ensures we meet client needs with precision,” emphasized Chairman Yang.

Localized Empowerment: Strengthening European Presence

XCMG announced strategic initiatives to deepen its European foothold:

  • XCMG Europe Training Center: Enhancing localized service through technical training, brand development, and sales support.
  • XCMG Italy Subsidiary and XCMG Europe Financial Leasing Co., Ltd.: Expanding market access and financial services to drive integrated “R&D-production-supply-sales-service-finance” growth.

The company celebrated a batch delivery ceremony at the event, handing over premium cranes, intelligent earthmoving equipment, new energy excavators, and road machinery to clients worldwide. This milestone underscores XCMG’s growing leadership in high-end, customized solutions.

Know-How: 240HR Transit Visa-Free in Shaanxi

XI’AN, China, April 9, 2025 /PRNewswire/ — This is a news release from the Shaanxi Provincial Department of Culture and Tourism:

Starting December 17, 2025, China has significantly relaxed and optimized its transit visa-free policy, offering travelers from qualifying countries an extended stay of up to 240 hours (10 days) instead of the previous 72 and 144-hour limits.

Shaanxi, a province famous for its rich cultural heritage and profound historical significance, offers much more than just a stopover. Thanks to the expanded scope of the visa-free policy, transit travelers are now free to explore not only Xi’an, but the entire province, unlocking a treasure trove of ancient sites, stunning landscapes, and local experiences.

Aside from Xi’an, what other cities can you explore in Shaanxi? Here is our list of the attractions across Shaanxi province:

Mount Huashan, Weinan: Known as one of China’s Five Great Mountains, Huashan offers breathtaking views and thrilling hikes along its dramatic cliffs and scenic peaks. Travels can take in the spiritual atmosphere and ancient temples dotting the landscape.

Bronze Ware Museum, Baoji: This museum showcases Shaanxi’s ancient craftsmanship, featuring exquisite bronze artifacts from the Western Zhou Dynasty (c. 11th century-771 BC) and beyond. It’s a must-visit for history enthusiasts keen to learn about China’s ancient metallurgy.

Zhenbei Pavilion, Yulin: This ancient site is a symbol of the region’s importance during the Ming Dynasty (1368-1644). Standing tall against the desert landscape, it offers a unique glimpse into China’s past.

Qingwei Tower Art Museum, Xianyang: The newly completed Qingwei Tower not only impresses with its ancient architectural style but also houses a modern museum inside. Qingwei Tower Art Museum features a large, comprehensive art museum that combines art collection, research, and global exchange.

Tianhan Tower, Hanzhong: Located along the Han River, this tower is known for its beautiful architectural design and as a symbol of the region’s historical significance.

Hualong Mountain, Ankang: Known for its picturesque landscapes and lush environment, Hualong Mountain is ideal for travelers seeking tranquility and natural beauty.

Tayun Mountain, Shangluo: Known for its rugged terrain and ancient temples, Tayun Mountain provides a perfect mix of outdoor adventure and cultural exploration.

As the new visa-free policy takes effect, more global visitors will be able to explore this province’s deep historical roots and vibrant modern life, making Shaanxi a must-visit destination on any traveler’s list.

bauma 2025: Zoomlion Leads Industry Trends with Green, Intelligent Technologies

MUNICH, April 9, 2025 /PRNewswire/ — Zoomlion Heavy Industry Science & Technology Co., Ltd. (“Zoomlion”; 1157.HK), a global leader in construction machinery, is showcasing its latest innovations at bauma 2025 under the theme “Greener Development, Brighter Future” from April 7 to 13 at Booth FS.905 at Messe München. Over 60 flagship products across nine major categories are on display, along with a debut lineup of intelligent and green system solutions in Europe. The Company also signed multiple international orders and cooperation agreements to accelerate and lead the construction machinery industry’s shift toward digital, intelligent, and green transformation.

bauma 2025: Zoomlion Leads Industry Trends with Green, Intelligent Technologies
bauma 2025: Zoomlion Leads Industry Trends with Green, Intelligent Technologies

Highlights at the Show

A highlight of Zoomlion’s lineup is the ZT72J-V, the highest telescopic boom lift in Europe, showcasing its leadership in high-end AWP development. The company is also unveiling 10 earthmoving machines, many featuring 5G remote control, AI panoramic monitoring, and electric-drive energy recovery. In the tower crane segment, the R800-40, the largest-tonnage Chinese model in Europe, secured strong interest with its safety, efficiency, and transportability. Zoomlion also introduced six concrete machines, including a 70-meter pump truck with a topology-optimized boom and smart mixer trucks with remote upgrades and intelligent diagnostics.

Zoomlion also showcased system solutions integrating industrial internet, AI, big data, and new energy technologies at bauma 2025. Its mining solution combines intelligent equipment and digital technologies, including unmanned trucks and remote control, to enable fully automated mining, digging, transporting, and unloading.

On the opening day, Zhan Chunxin, Chairman and CEO of Zoomlion, together with other senior executives, held in-depth discussions with customers and institutional representatives, reaffirming the company’s commitment to global development and delivering improved service worldwide.

Driving Growth Through a Global Industrial Ecosystem

With its unique overseas business ecosystem emphasizing the end-to-end digitalization and localization strategy, Zoomlion connects directly with customers and markets to deliver products that best meet market demands and expedite response times.

At bauma 2025, over 20 featured products are locally manufactured in Europe that meet the market demand and customer preference in terms of performance, technology, standards and design. Zoomlion’s 72-ton and 62-ton folding jib cranes, assembled in its German factory, meet the EN12999 standard and have received CE certification. The R800-40 flat-top tower crane, produced in China and assembled in Europe, ensures quick delivery and efficient service for customers.

On March 31, Zoomlion officially laid the cornerstone for Phase II of its German factory project in Waldlaubersheim. In February, Zoomlion’s AWP factory opened in Hungary, further deepening the group’s global industrial footprint.

Currently, Zoomlion operates globally with 11 R&D bases, 210 service centers, and sales in over 170 countries. Backed by 6,300 overseas staff, its network ensures fast delivery and strong growth.

“The bauma Germany has built a solid bridge for global industry exchange and cooperation enhancement. ZOOMLION will take this exhibition as an opportunity to explore innovative and cooperative development pathways using more high-end, intelligent, and green products to build our beautiful world together,” said Yuan Ye, Assistant President of Zoomlion.

Altair Wins 2025 Google Cloud Business Applications Partner of the Year Award for Manufacturing

Award recognizes partner that leveraged Google Cloud solutions that made a significant industry impact in business applications (manufacturing)

TROY, Mich., April 9, 2025 /PRNewswire/ — Altair, a global leader in computational intelligence, announced that it has received the 2025 Google Cloud Business Applications Partner of the Year Award for Manufacturing. Altair is being recognized for leveraging Google Cloud solutions to create comprehensive, compelling technology that made a significant impact in the manufacturing industry.

Altair has won the 2025 Google Cloud Business Applications Partner of the Year Award for Manufacturing.
Altair has won the 2025 Google Cloud Business Applications Partner of the Year Award for Manufacturing.

Altair won thanks to its geometric deep learning-based Altair® PhysicsAI™ solution, available in the Altair HyperWorks design and simulation platform. Powered by Google Cloud infrastructure, PhysicsAI transforms the design and simulation process by delivering design insights up to 1,000x faster than traditional solver-based simulations. By combining the power of geometric deep learning with Google Cloud’s scalability and performance, PhysicsAI is paving the way for faster, more sustainable design and engineering.

“We are honored to win a Google Cloud Partner of the Year Award for a second straight year. This recognition demonstrates how our best-in-class technology helps manufacturers reshape their workflows,” said Sam Mahalingam, chief technology officer, Altair. “More broadly, this award underscores how Altair’s unique approach to simulation, data, and AI solutions is transforming industries and providing tangible, impactful business results around the globe.”

“Google Cloud’s Partner Awards recognize partners who have created outsized value for customers through the delivery of innovative solutions and a high level of expertise,” said Kevin Ichhpurani, president, Global Partner Ecosystem, Google Cloud. “We’re proud to announce Altair as a 2025 Google Cloud Partner Award winner and celebrate their impact enabling customer success over the past year.”

Available through Altair One® on Google Cloud Marketplace, PhysicsAI enables faster iterations, smarter decision-making, and more innovative products. PhysicsAI makes data and simulation more accessible to non-data scientists, further expanding its potential and empowering teams with advanced, easy-to-use, simulation capabilities.

To learn more about the award, visit https://cloud.google.com/awards/partners. To learn more about Altair, visit https://altair.com/.

About Altair

Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair is part of Siemens Digital Industries Software. To learn more, please visit www.altair.com or sw.siemens.com.

Media contacts

Altair Corporate                                              

Bridget Hagan                                                  

+1.216.769.2658                                            

corp-newsroom@altair.com                    

Altair Europe/The Middle East/Africa

Altair Asia-Pacific

Louise Wilce

Man Wang

+44 (0)7392 437 635

86-21-5016635,,825

emea-newsroom@altair.com

apac-newsroom@altair.com